J.P. MORGAN HEALTHCARE CONFERENCE

January 13, 2015

Exhibit 99.1

Forward Looking Statements

Statements

in

this

presentation

that

are

not

strictly

historical,

including

any

statements

regarding

events

or

developments

that

we

believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities

laws.

There

are

a

number

of

important

factors

that

could

cause

actual

results,

developments

and

business

decisions

to

differ

materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any

such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the

markets we serve and financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates

and

cyclicality

of

markets

we

serve,

competition,

our

ability

to

develop

and

successfully

market

new

products

and

technologies

and

expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to

successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other

dispositions, contingent liabilities relating to acquisitions and divestures, our compliance with applicable laws and regulations

(including regulations relating to medical devices and the healthcare industry) and changes in applicable laws and regulations, our

ability to effectively address cost reductions, compliance and other changes in the healthcare industry, risks relating to potential

impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax

liabilities, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks

relating to product defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on

our operations and liquidity, our relationships with and the performance of our channel partners, commodity costs and surcharges,

our ability to adjust purchases and  manufacturing capacity to reflect market conditions, reliance on sole sources of supply, labor

matters,  international economic, political, legal and business factors, disruptions relating to man-made and natural disasters,

security breaches or other disruptions of our information technology systems and pension plan costs. Additional information

regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC

filings, including our 2013 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2014. These

forward-looking statements speak only as of the date of this presentation and the Company does not assume any obligation to

update or revise any forward-looking statement, whether as a result of new information, future events and developments or

otherwise.

All references in this presentation to earnings, revenues and other company-specific financial metrics relate only to the continuing

operations

of

Danaher’s

business,

unless

otherwise

noted.

All

references

in

this

presentation

to

“growth”

refer

to

year-over-year

growth unless otherwise indicated.

Diagnostics***

$4.8B

Strategic Platforms

Building a Global Science and Technology Company

Dental

Life Sciences

& Diagnostics

Test &

Measurement

Industrial

Technologies

Environmental

Communications*

$1.0B

Water Quality

$2.0B

Gilbarco Veeder-

Root

$1.6B

Instruments

$2.0B

Dental**

$2.9B

Product ID

$1.6B

Automation

$0.8B

Life Sciences

$2.5B

Figures represent 2014E adjusted revenues, reflecting adjustments described in these footnotes *Not including pending  NetScout transaction

**~$0.7B of 2014E revenue from Nobel Biocare and ~$2.2B of 2014E revenue from  Dental platform ;  ***~$0.2B of 2014E revenue from Devicor and ~$4.6B of 2014E revenue from Diagnostic platform

Danaher Business System

Current Update

Q4 played out largely as expected

Well positioned for 2015 and beyond

Adjusted EPS guidance range of $4.35-$4.45

Anticipate core revenue growth of 3-4%

Optimizing our portfolio to improve and sustain our market leading

positions

2015 Guidance

U.S.

solid;

Europe

stable;

High

growth

markets

(HGM)

lead

but

mixed

performance

23

rd

consecutive year of FCF>NI

~$4.0B of acquisitions announced or closed in 2014

Pending RMT of Communications business with NetScout

Divested $100M product line within Motion

Diagnostics

Life Sciences Tools

~$2.5B

2014E Revenue

65% Instruments

35% Consumables/Service

~$15B

Market

Size

~$4.8B*

2014E Adjusted Revenue

20% Instruments

80% Consumables/Service

~$25B

Market Size

*Represents 2014E adjusted revenue;

~$0.2B of 2014E revenue from Devicor and

~$4.6B of 2014E revenue from  Diagnostics Platform

Life Sciences & Diagnostics

Diagnostics Overview

Customers

Hospital labs

Reference labs

Hospital critical care

Histopathology labs

Growth Drivers

Healthcare expenditures increasing in HGMs

Greater investment in preventative and predictive

medicine

Skilled labor shortage & cost pressure driving

adoption of automated solutions

Market Details

Market

Size

~$25B

Growth

Rate

+MSD

2014E Financials

Adjusted

Revenue

~$4.8B*

*Represents 2014E adjusted revenues;

~$0.2B of 2014E revenue from Devicor and

~$4.6B

of

2014E

revenue

from

Diagnostics

Platform

Comprehensive product offering coupled with scaled, global presence

Geographic                   Mix   

Revenue Breakdown

NA

EU

HGM

ROW

6%

38%

23%

33%

Consumables/Service

Equipment

80%

20%

Building the Diagnostics Platform

$9B+ of capital committed since 2004; Significant M&A runway

~$300M

Revenue

~$4.8B**

2004

2014E

Core Lab      Urinalysis  Middleware  Microbiology

Histology     Adv. Staining     Histology Consumables   Digital Pathology          ISH/FISH      Biopsy

Blood Gas

Immunoassay

Hemoglobin        

Beckman Dx

Leica

Biosystems

Radiometer

2004

2006

2008

2012

2014

2010

*

*Pending, subject to customary closing conditions

**Represents 2014E adjusted revenues;~$0.2B

of 2014E revenue from Devicor and ~$4.6B of 2014E

revenue from Diagnostics Platform

What You Will Hear Today

Driving +MSD core growth with significant runway for margin improvement

Accelerating growth through organic investments in new

products and feet-on-the street

DBS improving customer satisfaction and operational

performance while funding growth

Acquisitions expanding addressable market and breadth of

product offerings

Growth Investments –

LS&D

* Not yet commercially available in the US

Increasing product launch cadence at Beckman Dx

Key product launches at LBS

Continuing to invest in HGMs and R&D

+MSD core revenue growth in 2014E with 2X revenue from new products

Automation solutions: Connectivity for DxH800 and FDA

clearance for PowerExpress solutions

Menu expansion: Vitamin D* and Automated AMH*

(fertility)

Enter Molecular Dx with Veris*; high volume fully

automated PCR solution, very fast turn-around time,

random access, multiplexing capabilities

FDA clearance for HER2 IHC

First SaaS product offering with Aperio ePathAccess

>10% increase in HGM feet-on-street across Dx in 2014E

Joint Dx Software Development Center in Bangalore

Investing for Growth –

Beckman

DBS improving customer satisfaction, expanding margin and funding growth

*Based on IMV customer ranking among major IVD players: SDR3

Remediated quality management

system

Increased instrument reliability >50%

Improved to #1 (from #4) for service

delivery in US*

Key Performance

Indicator

2012

2013

2014E

OMX (bps)

>300

>150

>150

WC turn improvement

~0.5

>0.5

>0.5

Growth headcount

>200

>200

>200

# of reagent SKUs on stock-out

Reduced

>75%

FDA 510(k) clearance of Troponin Assay

Formal closure of all FDA warning letters

Iris Acquisition

OP margin >+2,000 bps since acquisition; Double-digit ROIC in year 2

2013

2014E

Expanded offering for core hospital lab

Attractive market and business model

Beckman’s scale accelerating growth

and cost savings

Leader in automated urinalysis testing

Beckman’s first bolt-on acquisition

~$400M market growing +MSD/HSD

~70% consumables/~30% equipment

Leveraging access in HGMs and in

Developed markets

Increasing FOS and R&D resources,

funded through back-office synergies

Revenue

>10% growth

Op Profit

~2X

Devicor Acquisition

LBS broadest workflow coverage in anatomical pathology

Positions LBS at the front-end of breast cancer

workflow

Installed-base business model

~80% consumables and 70% gross margin

Attractive business model and margin profile

with opportunity to improve using DBS

Control sample handling/processing to improve diagnostic

quality

Runway to expand into other biopsy market segments

Opportunity for integrated workflow from biopsy to

diagnosis

A leader in vacuum-assisted breast biopsy

$400M market segment growing +MSD

Complementary Workflow

LBS broadest workflow coverage in anatomical pathology

MammoPort

with Revolve tray   

(under

development)       

Leica Tissue Processor

Customer value proposition

Increased sample integrity and tissue quality

Time reduction to accession and to processing of biopsies

Automated data tracking from biopsy to path lab => reduced risk of

sample mislabeling

Summary

Accelerating growth through organic investments in new

products and feet-on-the street

DBS improving customer satisfaction and operational

performance while funding growth

Acquisitions expanding addressable market and breadth of

product offerings

Driving +MSD core growth with significant runway for margin improvement